Summary: Patients with type 2 diabetes (DMT2) are at a higher cardiovascular risk, including the risk of heart failure (HF) development, in comparison to the healthy population. Recent clinical trials revealed that type 2 sodium-glucose cotransporter (SGLT2) inhibitors not only improved blood glucose control but also reduced risk of cardiovascular events and hospitalizations due to HF in patients with DMT2. In addi-tion, clinical benefits have also been observed in patients with HF without DMT2. The aim of this review is to summarize recent clinical trials and scientific reports, and to analyze the possible mechanisms of cardioprotective effect of SGLT2 inhibitors in patients with HF and their clinical impact on cardiovascular events.